Tacrolimus Exposure in Kidney Transplantation

Seoul National University

Status: Enrolling

Conditions: Kidney Transplant Rejection

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06348446

FY20-2963

Details and patient eligibility

About

Using CDW data from 5 tertiary hospitals in Korea, this study identify the optimal range of trough level that can prevent adverse outcome in the early periods after transplantation.

Enrollment: 12,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Renal transplant recipients between January 1, 2005 through December 31, 2014 in one of the five participating centers
• Patients receiving oral tacrolimus as one of the main immunosuppressant at the start of the defined cohort time (i.e. at post-transplant 2 months for the analysis of 1-year outcomes and at post-transplant 12 months for the analysis of 6-year outcomes)

Exclusion criteria

• Graft failure occurring within the first 2 month of transplantation
• Mortality of any cause occurring within the first 2 month of transplantation
• Patients moving centers during the study period
• Patients who have received other organ transplantation(s) besides renal transplantation in the defined period